<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00909584</url>
  </required_header>
  <id_info>
    <org_study_id>TLK199.2103</org_study_id>
    <nct_id>NCT00909584</nct_id>
  </id_info>
  <brief_title>Study of Ezatiostat (Telintra Tablets) for Treatment of Severe Chronic Neutropenia</brief_title>
  <official_title>Phase 2 Randomized Study of Ezatiostat Hydrochloride (Telintraâ„¢, TLK199 Tablets) for Treatment of Severe Chronic Neutropenia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Telik</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Telik</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter Phase 2 randomized parallel-group study to determine the effect of
      Telintra treatment on severe chronic neutropenia. Patients will be randomized to Telintra or
      enter an observation period with an option to crossover to Telintra treatment in a 1:1
      allocation.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Study TLK199.2103 was terminated for business reasons.
  </why_stopped>
  <start_date>April 2009</start_date>
  <completion_date type="Actual">May 2013</completion_date>
  <primary_completion_date type="Actual">May 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective absolute neutrophil count (ANC) response rate</measure>
    <time_frame>18 Months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of infections, oropharyngeal ulcers and antibiotic use</measure>
    <time_frame>18 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence and duration of hospitalizations</measure>
    <time_frame>18 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FACT-N quality of life assessment</measure>
    <time_frame>18 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety assessments</measure>
    <time_frame>18 Months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">9</enrollment>
  <condition>Severe Chronic Neutropenia</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>4-Week dose equilibration period with Telintra followed by 4 month treatment period</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>4 Month observation period with standard of care treatment and option to crossover to Telintra treatment for 4 week dose equilibration followed by 4 week treatment period</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ezatiostat Hydrochloride</intervention_name>
    <description>Starting Dose 2000 mg orally per day in two divided doses with dose to increase or decrease to achieve target median ANC (Range 1,500-10,000 cells/uL)</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Telintra tablets</other_name>
    <other_name>TLK199 Tablets</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Confirmed Idiopathic Severe Chronic Neutropenia

          -  ECOG performance status of 0-2

          -  Adequate liver and renal function

          -  Adequate Red Blood Cell and Platelet counts

        Exclusion Criteria:

          -  Prior treatment of SCN

          -  Non-Idiopathic types of SCN, ie. cyclic, congenital

          -  History of chromosomal abnormalities, myelodysplasia, hematologic malignancy, aplastic
             anemia, systemic lupus erythematosus, rheumatoid arthritis (Felty's syndrome), or
             other collagen diseases, and drug-induced neutropenia, autoimmune neutropenia

          -  Use of granulocyte colony stimulating factors (G-CSF), glucocorticoids, gamma
             globulin, lithium or investigational drug(s) within one month of enrollment

          -  History of bone marrow transplantation or stem cell support
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gail Brown, MD</last_name>
    <role>Study Director</role>
    <affiliation>Telik</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Center for Cancer and Blood Disorders</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Michigan Hospital</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109-0238</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Care Centers of South Texas</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Washington Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 26, 2009</study_first_submitted>
  <study_first_submitted_qc>May 27, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 28, 2009</study_first_posted>
  <last_update_submitted>November 20, 2013</last_update_submitted>
  <last_update_submitted_qc>November 20, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 25, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hematology</keyword>
  <keyword>Neutropenia</keyword>
  <keyword>SCN</keyword>
  <keyword>Severe Chronic Neutropenia</keyword>
  <keyword>Idiopathic</keyword>
  <keyword>Telintra</keyword>
  <keyword>ezatiostat hydrochloride</keyword>
  <keyword>ezatiostat</keyword>
  <keyword>TLK199</keyword>
  <keyword>Glutathione</keyword>
  <keyword>Glutathione analog</keyword>
  <keyword>Glutathione Transferase</keyword>
  <keyword>Glutathione Transferase inhibitor</keyword>
  <keyword>Glutathione Transferase P1-1 inhibitor</keyword>
  <keyword>GSTp1-1 inhibitor</keyword>
  <keyword>Apoptosis</keyword>
  <keyword>Differentiation</keyword>
  <keyword>Enzyme inhibitor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neutropenia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

